Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
39results about How to "Prolonged bleeding time" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Tissue treatment by normothermic heating
InactiveUS6921374B2Difficult to treatProlonged bleeding timeCannulasEnemata/irrigatorsRoom temperatureTissue temperature
An apparatus for treating tissue in a tissue treatment area includes a heater that does not contact the tissue. The apparatus may be attached to the skin of a person to form a treatment volume about the tissue to be treated. The heater, supported at the layer, is held near the tissue to be treated, out of contact with the tissue. The apparatus includes a controller to cause the heater to raise the temperature of tissue in the tissue treatment area to a temperature in a range from a pretreatment temperature to 38° C. The controller may include means that cause the heater to operate over a therapeutic sequence, that cycle the heater on and off, that provide selectable average temperature values, that cause the heater to operate over an average temperature range, that cause the heater to operate at an average temperature over a therapy cycle, or that cause the heater to operate at an average temperature over a therapeutic sequence.
Owner:3M INNOVATIVE PROPERTIES CO +1
Normothermic tissue treatment
InactiveUS6840915B2Drying of woundPrevent evaporationCannulasEnemata/irrigatorsElectrical resistance and conductanceAdhesive
A non-contact controllable heater wound covering and method having a peripheral sealing ring covered by a layer to which is attached a heater and this assembly is attached to the skin with an adhesive so that the heater is held proximate the wound area in a non-contact position. The layer and peripheral sealing ring together define a treatment volume proximate the wound. The wound covering includes a programmable active heater control and the sealing ring may dispense water to control the humidity of the treatment volume. One form of active heat is an electrical resistive filament in variable geometric shapes providing versatility in application of heat to different types of wounds and wound area geometries. Another form of active heat is the transfer of a heated gas to the wound covering.
Owner:GEN ELECTRIC CAPITAL
Piperazinones, their production and use
InactiveUS6020334ALow toxicityEasy to useOrganic active ingredientsOrganic chemistryCell adhesionAdhesion process
The present invention provides compounds and medicines effective for prophylaxis and therapy of various diseases by controlling or inhibiting cell-adhesion. Especially, the compounds of this invention perform platelet aggregation action without remarkable elongation of hemorrhagic period and can be used as a safe and long-acting antithrombotic drug as compared with known substances showing the same activity. Compounds of this invention are piperazinones of the formula
Owner:TAKEDA PHARMACEUTICALS CO LTD
Synergistic phytochemical composition and a process for preparation thereof
ActiveUS20130053339A1Cause constipationIncreased riskBiocideOrganic active ingredientsChronic painExcipient
The present invention provides a synergistic phytochemical composition from Curcuma longa possessing analgesic and anti inflammatory activity used for management of chronic pain and treatment of osteoarthritis. The composition comprises Curcuma longa oil and Curcuma longa water extract. The relative amounts of these materials may be 0.5-5% by weight and 95-99.5% by weight respectively; and optionally pharmaceutically acceptable excipients.The present invention also provides a process for preparing the composition.
Owner:NATURAL REMEDIES PVT LTD
Anticoagulation Agent and Uses Thereof
InactiveUS20090148383A1High affinity bindingTherapy is simplePeptide/protein ingredientsAntibody mimetics/scaffoldsAnticoagulantCoagulation Disorder
The present invention provides an anticoagulant agent including a first element capable of inhibiting coagulation and a second element capable of targeting an activated platelet wherein upon administration of element directs the first element to the activated platelet. Also provided is a probe for detecting a blood vessel abnormality including (a) a binding element capable of targeting an activated platelet and (b) a label. Applicant has shown that agents and probes directed to activated platelets are useful in the diagnosis and therapy of coagulation disorders.
Owner:BAKER IDI HEART & DIABETES INST HLDG LTD
Cyclopropanecarboxylic acid derivative
InactiveUS20130012532A1High activityGood characterAntibacterial agentsBiocidePulmonary artery embolismHydrogen atom
A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein R1 represents a C1 to C6 alkyl group which may be substituted by one to three groups selected from substituent group A, or the like (substituent group A: a hydroxy group, a halogeno group, a cyano group, a nitro group, an amino group, a carboxy group, a C1 to C3 alkyl group, etc.); R2, R3, and R8 each independently represent a hydrogen atom or a C1 to C3 alkyl group; R4, R5, R6, R7, R9, and R10 each independently represent a hydrogen atom or the like; and R11 represents a hydrogen atom or the like, has TAFIa enzyme inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, or the like.
Owner:DAIICHI SANKYO CO LTD
Composition and method for treating and preventing musculoskeletal and connective tissue disorders
ActiveUS20090192201A1Promote angiogenesisPromote blood circulationBiocideInorganic active ingredientsEtiologyDisease
The present invention relates to a pharmaceutical composition and method for treating and preventing musculoskeletal and connective tissue diseases of unknown etiology, such as different forms of arthritis and other rheumatic conditions, comprising a combination of therapeutic agents that improve the processes of blood circulation and angiogenesis in the affected tissues, as well as other supporting therapies. Among the components of herein proposed pharmaceutical composition, are: vitamin K, polyunsaturated fatty acids (blood thinner), and niacin (vasodilator and hypolipidemic agent).
Owner:SELMAN HOUSEIN SOSA GUILLERMO
Compound soft lutein capsule and its prepn process
ActiveCN1771919AAvoid formingImprove the level ofSenses disorderHydroxy compound active ingredientsSenile macular degenerationΑ-linolenic acid
The present invention discloses one kind of composite soft lutein capsule and its preparation process. The content in each capsule includes lutein1-10 mg, alpha-linolenic acid 100-300 mg, vitamin A 0-5 mg and vitamin E 0-7.5 mg; and the capsule covering consists of gelatin, glycerin, water, and opacifier or edible color. The lutein is prepared through supercritical CO2 extraction process, and has no pollutant and organic solvent residue. The composite soft lutein capsule product has stable quality and high bioavailability, and has certain preventing and treating effect on senile macular degeneration, cataract and cardiac and cerebral vascular diseases.
Owner:JIANGSU ACAD OF AGRI SCI
Intrauterine sustained control release drug delivery system adopting biodegradation material, and preparation method thereof
ActiveCN102743328AAvoid bleedingAvoid reactionOrganic active ingredientsPharmaceutical delivery mechanismControl releaseProgesterones
The present invention relates to a female intrauterine drug delivery system, and more particularly to an intrauterine sustained control release drug delivery system adopting a biodegradation material, and a preparation method thereof. The present invention provides an intrauterine sustained control release drug delivery system adopting a biodegradation material, and a preparation method thereof, wherein the system has characteristics of short length, light weight, efficiency, and reversibility. The system comprises a sustained control release pipe, a drug core and a tail filament, wherein the sustained control release pipe is wrapped on the external of the drug core, the tail filament is positioned between the sustained control release pipe and the drug core or is accommodated in the middle of the drug core, the drug core is a rod prepared by blending progesterone or an available intrauterine sustained control release drug and a biodegradable polymer, and the sustained control release pipe is made of a biodegradable polymer. The system of the present invention has characteristics of no stent, no copper ion, safety, practicality, and simple placement technology.
Owner:杨立群
Biologic devices for hemostasis
ActiveUS20090304804A1Few stepsLess blood lossBiocidePeptide/protein ingredientsVeinSerum protein albumin
A microscopic protein device and the method of manufacture and the use of such a device for hemostasis. The device, made with biologic material such as serum albumin from a human or animal source, is less than five micron in any one dimension and typically less than one micron in diameter. It does not have any other biological or drug molecules attached to it in vitro. However, the device has properties that allow it to capture, concentrate, carry or bind biomodifying molecules, such as coagulation factor(s), or potentially other drugs, after exposure to plasma in vitro; and possibly in vivo as well. After infusion of said device intravenously inside the body, hemostatic effects can be demonstrated.
Owner:PTLNV LLC SERIES FIVE 5
Inhibition of phosphoinositide 3-kinase beta
InactiveUS7598377B2Specific inhibitionProlonged bleeding timeOrganic active ingredientsOrganic chemistryAntithrombotic treatmentKinase inhibition
The present invention relates to selective inhibitors of phosphoinositide (PI) 3-kinase β, use of the selective inhibitors in anti-thrombotic therapy, and a method for screening compounds useful for the new anti-thrombotic therapy by detecting selective inhibitory activity of PI 3-kinase β of the compound. The invention also relates to novel compounds that are inhibitors of PI 3-kinase.
Owner:ASTRAZENECA AB
Composition and method for treating and preventing musculoskeletal and connective tissue disorders
ActiveUS8211947B2Increased riskPromote angiogenesisBiocideInorganic active ingredientsEtiologyDisease
The present invention relates to a pharmaceutical composition and method for treating and preventing musculoskeletal and connective tissue diseases of unknown etiology, such as different forms of arthritis and other rheumatic conditions, comprising a combination of therapeutic agents that improve the processes of blood circulation and angiogenesis in the affected tissues, as well as other supporting therapies. Among the components of herein proposed pharmaceutical composition, are: vitamin K, polyunsaturated fatty acids (blood thinner), and niacin (vasodilator and hypolipidemic agent).
Owner:SELMAN HOUSEIN SOSA GUILLERMO
Novel intrauterine sustained control release drug delivery system and preparation method thereof
ActiveCN102743329AAvoid bleedingAvoid reactionOrganic active ingredientsPharmaceutical delivery mechanismProgesteronesBiodegradable polymer
The present invention relates to a female intrauterine drug delivery system, and more particularly to a novel intrauterine sustained control release drug delivery system and a preparation method thereof. The present invention provides a novel intrauterine sustained control release drug delivery system and a preparation method thereof, wherein the system has characteristics of short length, light weight, efficiency, and reversibility. The system comprises a sustained control release pipe, a drug core and a tail filament, wherein the sustained control release pipe is wrapped on the external of the drug core, the tail filament is positioned between the sustained control release pipe and the drug core or is accomodated in the middle of the drug core, the drug core is a rod prepared by blending progesterone or an available intrauterine sustained control release drug and a biodegradable polymer, and the sustained control release pipe is made of a silicon rubber. The system of the present invention has characteristics of no stent, no copper ion, safety, practicality, and simple placement technology.
Owner:杨立群
Biologic devices for hemostasis
ActiveUS9114127B2Few stepsLess blood lossBiocidePeptide/protein ingredientsVeinSerum protein albumin
A microscopic protein device and the method of manufacture and the use of such a device for hemostasis. The device, made with biologic material such as serum albumin from a human or animal source, is less than five micron in any one dimension and typically less than one micron in diameter. It does not have any other biological or drug molecules attached to it in vitro. However, the device has properties that allow it to capture, concentrate, carry or bind biomodifying molecules, such as coagulation factor(s), or potentially other drugs, after exposure to plasma in vitro; and possibly in vivo as well. After infusion of said device intravenously inside the body, hemostatic effects can be demonstrated.
Owner:PTLNV LLC SERIES FIVE 5
Chinese medicinal composition with Ginseng and Ginkgo leaves
InactiveCN1939367AHas anti-hypoxic effectIncrease dosagePowder deliveryLyophilised deliveryCurative effectGinkgo biloba
A composite Chinese medicine with high curative effect and low toxic by-effect is prepared from ginseng and gingko leaf in weight ratio of 1:2.
Owner:孙毅
Aorta blocking balloon device based on 18F-FDG detection and positioning
ActiveCN114587480AIncrease the success rate of blockingLower performance requirementsDiagnostic recording/measuringSensorsBleeding timeCatheter
The invention belongs to the technical field of medical instruments, and particularly relates to an aorta blocking balloon device based on 18F-FDG detection and positioning, which comprises a catheter, a balloon is arranged at the front end of the catheter, an injection tube communicated with the balloon penetrates through the interior of the catheter, and an injector communicated with the injection tube is arranged at the rear end of the catheter; before aorta blocking hemostasis is executed, the device can assist in determining the general anatomical orientation of the balloon in the body and increasing the success rate of disposable balloon blocking, and has the following advantages that firstly, the device has lower requirements on the technical ability and experience of first-aid implementers, and can be mastered according to program operation after simple training; secondly, the 18F-FDG is a common medical medicament, the availability and the medication cost can be controlled, and correspondingly, the handheld gamma ray detector for detecting the 18F-FDG is relatively low in cost; the technical operation procedure is simple, and the risk of additionally increasing bleeding time is small; fourthly, the half-life period of 18F is short, and secondary injury to patients is small.
Owner:中国人民解放军火箭军特色医学中心
Chimeric Kunitz Domains and their Use
InactiveUS20090170766A1Prolonged bleeding timeShorten bleeding timeFungiNervous disorderTissue factorHumans tissues
The present invention relates to chimeras of human tissue factor inhibitor domain 1 with natural and non-natural Kunitz domains, and their preparation and use.
Owner:BAYER SCHERING PHARMA AG
Cyclopropanecarboxylic acid derivative
InactiveUS8946443B2High activityGood characterAntibacterial agentsBiocidePulmonary artery embolismHydrogen atom
A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein R1 represents a C1 to C6 alkyl group which may be substituted by one to three groups selected from substituent group A, or the like (substituent group A: a hydroxy group, a halogeno group, a cyano group, a nitro group, an amino group, a carboxy group, a C1 to C3 alkyl group, etc.); R2, R3, and R8 each independently represent a hydrogen atom or a C1 to C3 alkyl group; R4, R5, R6, R7, R9, and R10 each independently represent a hydrogen atom or the like; and R11 represents a hydrogen atom or the like, has TAFIa enzyme inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, or the like.
Owner:DAIICHI SANKYO CO LTD
Hexadecapeptide compound and preparation method and application thereof
InactiveCN108530519AProlonged bleeding timeLow toxicityPeptide/protein ingredientsPeptide preparation methodsProlonged bleeding timeChemical compound
The invention relates to a hexadecapeptide compound and a preparation method and application thereof. The polypeptide sequence of the hexadecapeptide compound is one or more of RTGACFCVIYNGILYP, or the sequence with the 1-site amino acid R replaced by K, the sequence with the 2-site amino acid T replaced by S, the sequence with the 8-site amino acid V replaced by I or L, the sequence with the 9-site amino acid I replaced by V or L, the sequence with the 11-site amino acid N replaced by Q, the sequence with the 13-site amino acid I replaced by V or L, and the sequence with the 14-site amino acid L replaced by V or I. The hexadecapeptide compound has the functions of prolonging bleeding time, remarkably inhibiting platelet aggregation, and preventing thrombosis, has low toxicity, and has broad application prospects in preparing anti-platelet aggregation or antithrombotic drugs, drug components or prodrugs. The preparation method has high yield and simple process.
Owner:GUANGDONG MEDICAL UNIV
A kind of sixteen peptide compound and its preparation method and application
InactiveCN108530519BProlonged bleeding timeLow toxicityPeptide/protein ingredientsPeptide preparation methodsBleeding timeThrombus
The invention relates to a hexadecapeptide compound and a preparation method and application thereof. The polypeptide sequence of the hexadecapeptide compound is one or more of RTGACFCVIYNGILYP, or the sequence with the 1-site amino acid R replaced by K, the sequence with the 2-site amino acid T replaced by S, the sequence with the 8-site amino acid V replaced by I or L, the sequence with the 9-site amino acid I replaced by V or L, the sequence with the 11-site amino acid N replaced by Q, the sequence with the 13-site amino acid I replaced by V or L, and the sequence with the 14-site amino acid L replaced by V or I. The hexadecapeptide compound has the functions of prolonging bleeding time, remarkably inhibiting platelet aggregation, and preventing thrombosis, has low toxicity, and has broad application prospects in preparing anti-platelet aggregation or antithrombotic drugs, drug components or prodrugs. The preparation method has high yield and simple process.
Owner:GUANGDONG MEDICAL UNIV
Inhibition Of Phosphoinositide 3-Kinase Beta
InactiveUS20080319021A1Specific inhibitionProlonged bleeding timeBiocideOrganic chemistryAntithrombotic treatmentKinase inhibition
The present invention relates to selective inhibitors of phosphoinositide (PI) 3-kinase β, use of the selective inhibitors in anti-thrombotic therapy, and a method for screening compounds useful for the new anti-thrombotic therapy by detecting selective inhibitory activity of PI 3-kinase β of the compound. The invention also relates to novel compounds that are inhibitors of PI 3-kinase.
Owner:ASTRAZENECA AB
Sulfated Lachnum extracellular polysaccharide and application thereof in anticoagulant drugs
InactiveCN104974270AProlonged bleeding timeProlong clotting timeOrganic active ingredientsBlood disorderSulfationBleeding time
The invention belongs to the field of medical immunity, and provides a sulfated Lachnum extracellular polysaccharide and application thereof in anticoagulant drugs. The sulfated Lachnum extracellular polysaccharide is prepared by carrying out sulfur trioxide-pyridine composite sulfation modification on Lachnum polysaccharide LEP-1 which is secreted and extracted from Lachnum YM281. The pharmacological experiment proves that the sulfated Lachnum extracellular polysaccharide has prolonging actions on mouse bleeding time (BT) and mouse coagulation time (CT) under the conditions of both low dose (30 mg / kg) and high dose (90 mg / kg), which indicates that the sulfated Lachnum extracellular polysaccharide has an anticoagulation action, thereby providing a new way for anticoagulation research.
Owner:HEFEI UNIV OF TECH
Anticoagulation agent and uses thereof
InactiveUS20090317329A2Extension of timeProlonged bleeding timePeptide/protein ingredientsAntibody mimetics/scaffoldsAnticoagulant AgentCoagulation Disorder
The present invention provides an anticoagulant agent including a first element capable of inhibiting coagulation and a second element capable of targeting an activated platelet wherein upon administration of the agent to a subject the second element directs the first element to the activated platelet. Also provided is a probe for detecting a blood vessel abnormality including (a) a binding element capable of targeting an activated platelet and (b) a label. Applicant has shown that agents and probes directed to activated platelets are useful in the diagnosis and therapy of coagulation disorders.
Owner:BAKER IDI HEART & DIABETES INST HLDG LTD
Application of heparin iron compound in treatment of chronic inflammatory anemia
ActiveCN108186675AReduce hepcidin levelsImprove the level ofHeavy metal active ingredientsOrganic active ingredientsPhysiologyMedicine
The invention discloses application of a heparin iron compound in treatment of chronic inflammatory anemia. The heparin iron nano-compound is proved to have effects of obviously reducing hepcidin content, increasing hemoglobin level in an inflammatory anemia model, significantly lowering the transcription of the hepcidin in HepG2 cells at a lower concentration, and reducing the anticoagulant activity of the hepcidin. The heparin iron nano-compound is prepared and is safely applied to the treatment of the inflammatory anemia taking the hepcidin as a target, and the bleeding risk is avoided.
Owner:SHANDONG UNIV
A kind of sulfated Trichomonas exopolysaccharide and its application in anticoagulant medicine
InactiveCN104974270BProlonged bleeding timeProlong clotting timeOrganic active ingredientsBlood disorderSulfationBleeding time
The invention belongs to the field of medical immunity, and provides a sulfated Lachnum extracellular polysaccharide and application thereof in anticoagulant drugs. The sulfated Lachnum extracellular polysaccharide is prepared by carrying out sulfur trioxide-pyridine composite sulfation modification on Lachnum polysaccharide LEP-1 which is secreted and extracted from Lachnum YM281. The pharmacological experiment proves that the sulfated Lachnum extracellular polysaccharide has prolonging actions on mouse bleeding time (BT) and mouse coagulation time (CT) under the conditions of both low dose (30 mg / kg) and high dose (90 mg / kg), which indicates that the sulfated Lachnum extracellular polysaccharide has an anticoagulation action, thereby providing a new way for anticoagulation research.
Owner:HEFEI UNIV OF TECH
Compound soft lutein capsule and its preparing process
ActiveCN100400038CAvoid formingImprove the level ofSenses disorderHydroxy compound active ingredientsSenile macular degenerationΑ-linolenic acid
The present invention discloses one kind of composite soft lutein capsule and its preparation process. The content in each capsule includes lutein1-10 mg, alpha-linolenic acid 100-300 mg, vitamin A 0-5 mg and vitamin E 0-7.5 mg; and the capsule covering consists of gelatin, glycerin, water, and opacifier or edible color. The lutein is prepared through supercritical CO2 extraction process, and has no pollutant and organic solvent residue. The composite soft lutein capsule product has stable quality and high bioavailability, and has certain preventing and treating effect on senile macular degeneration, cataract and cardiac and cerebral vascular diseases.
Owner:JIANGSU ACAD OF AGRI SCI
Xueshuantongmai drug, preparation method and content determination method
ActiveCN111588763BConvenient treatmentEnhance cell viabilityAnthropod material medical ingredientsComponent separationDiseaseEfficacy
Owner:唐宏
Fibrinogenolytic proteases with thrombolytic and antihypertensive activities: medical application and novel process of expression and production
InactiveUS20030039644A1Improve thermal stabilityHigh activityNervous disorderFibrinogenVascular diseaseProteinase activity
The present invention provides a process of producing highly purified proteases. The invention further provides the use of such purified proteases in treating cardiovascular disorders, including hypertension, stroke and thrombosis.
Owner:ACAD SINIC
Anticoagulation agent and uses thereof
InactiveCN101237879AAvoid prolonged bleedingProlonged bleeding timePeptide/protein ingredientsAntibody ingredientsBlood vessel abnormalPlatelet
The present invention provides an anticoagulant agent including a first element capable of inhibiting coagulation and a second element capable of targeting an activated platelet wherein upon administration of the agent to a subject the second element directs the first element to the activated platelet. Also provided is a probe for detecting a blood vessel abnormality including (a) a binding element capable of targeting an activated platelet and (b) a label. Applicant has shown that agents and probes directed to activated platelets are useful in the diagnosis and therapy of coagulation disorders.
Owner:贝克医药研究所
Application of campsis radicans polysaccharide to preparation of anticoagulant medicines
InactiveCN102552308BProlong clotting timeExtension of timeOrganic active ingredientsBlood disorderBleeding timeMedicine
The invention relates to application of a campsis radicans polysaccharide, in particular to application of a campsis radicans polysaccharide to the preparation of anticoagulant medicines. The action of the campsis radicans polysaccharide on the blood coagulation time of capillaries and bleeding time of tail tips of mice is measured by intracorporeal administration; and the influence of the campsis radicans polysaccharide on the thrombin time, prothrombin time, active part thromboplastin time and plasma recalcification time of the mice is measured. Anticoagulation experiments indicate that thecampsis radicans polysaccharide can prolong the blood coagulation time of the capillaries and bleeding time of the tail tips of the mice obviously, and prolong the thrombin time, prothrombin time andplasma recalcification time of the mice obviously, and display that the activity of exogenous blood coagulation factors is inhibited, so that the generation of hemaleucin is inhibited, and the thrombin time is prolonged obviously. Experiment results prove that the campsis radicans polysaccharide has an obvious anticoagulation effect.
Owner:SUZHOU UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com